These findings coupled with the fact that 20 to 30% of patients are non-responders to aspirin, clopidogrel or both agents [ 436] suggest that reliable measures of platelet function would be useful in the setting of the bleeding trauma patient to guide clinicians on the use of platelet transfusion or other reversal agents.
In addition, radial arterial access for PCI has been proven to offer an advantage in ACS setting with increased risk of bleeding by decreasing the risk of vascular complications and mortality within 30 days when compared to femoral arterial access [ 2].
The thrombocytopenia was manageable with PBSC support, but makes this regimen unlikely to be applied outside the research setting because of the risk of bleeding, particularly if combined with other predisposing factors.
Thus, this study systematically assembled the best evidence from randomized clinical trials (RCTs) and observational studies conducted in the real-life setting to evaluate the risk of bleeding and mortality in the population with AF treated with warfarin and other VKAs.
In randomized trials, low-dose (LD) and high-dose (HD) aspirin (ASA) are equally effective in reducing ischemic complications, but HD ASA is associated with an increased risk of bleeding in the setting of dual antiplatelet therapy after percutaneous coronary intervention (PCI).
61 96 The management of bleeding in the setting of systemic anticoagulation is an ongoing clinical challenge.
It is unclear what laboratory abnormalities are predictive of bleeding in the setting of hypothermia.
The risk of bleeding events in the setting of thrombocytopenia underlies the use of prophylactic platelet transfusions.
This technique has not gained widespread use, and some have suggested that it would be inappropriate in the setting of extracorporeal membrane oxygenation (ECMO) because of bleeding risk.
